Pharmaceuticals Germany

Germany Long-Acting HIV Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Germany Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Germany · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $91.3 Mn Placeholder estimate
Estimate 2025 $107.9 Mn 3.7% of the global market
Projected 2034 $485.7 Mn 350.4% Adds $377.9 Mn over 9 forecast years
CAGR 2025–2034 18.2% Faster than 86% of 180 Pharmaceuticals markets here
Key players 4
  • Germany is 3.75% of the global market.
  • In Europe, the largest is Germany (this report) at $107.9 Mn.
  • Fastest growing: Russia at 19.6% a year.
  • Germany ranks 1st of 6 by size in Europe.

Market size projection

Germany

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$377.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, Germany
YearMarket sizeChange that yearSince 2025
2024 (estimate) $91.3 Mn — —
2025 (base) $107.9 Mn +$16.6 Mn —
2026 (forecast) $127.5 Mn +$19.6 Mn +18.2%
2027 (forecast) $150.7 Mn +$23.2 Mn +39.7%
2028 (forecast) $178.1 Mn +$27.4 Mn +65.1%
2029 (forecast) $210.5 Mn +$32.4 Mn +95.2%
2030 (forecast) $248.9 Mn +$38.3 Mn +130.7%
2031 (forecast) $294.1 Mn +$45.3 Mn +172.7%
2032 (forecast) $347.7 Mn +$53.5 Mn +222.3%
2033 (forecast) $411.0 Mn +$63.3 Mn +281%
2034 (forecast) $485.7 Mn +$74.8 Mn +350.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Germany Long-Acting HIV Treatment Market Analysis at a glance
Market size, 2025$107.9 Mn placeholder estimate
Forecast, 2034$485.7 Mn placeholder estimate
Growth (CAGR), 2025–203418.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsUse, drug and end user (see all)
Key playersViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Regulator in GermanyBfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
Active clinical trials5 in GermanySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Germany Long-Acting HIV Treatment Market Analysis Executive Summary

Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.

Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).

Bar chart: Germany Long-Acting HIV Treatment market size, 2024–2034, placeholder estimates. $91.3 Mn in 2024, $107.9 Mn in 2025 and $485.7 Mn in 2034, 18.2% CAGR.
Germany Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Germany Long-Acting HIV Treatment Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.

Competitive Landscape for Long-Acting HIV Treatment Market in Germany

The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in Germany

Long-Acting HIV Treatment in Germany: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.⁠[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.⁠[2] ClinicalTrials.gov lists 5 studies on Long-Acting HIV Treatment that are recruiting, active or about to start in Germany.⁠[3] New HIV infections: 2,300 people in 2024, the latest WHO figure for Germany.⁠[4]

[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, New HIV infections (people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Long-Acting HIV Treatment in context

Germany compared

  • New HIV infections: 2,300 people (2024). World: 1.2 million people (2025). 4th highest of the 5 countries we cover in Europe.[1]
  • Health spending per person: 6,849 US$ per person (2024). World: 1,317 US$ per person (2023). Highest of the 6 countries we cover in Europe.[2]
  • Doctors: 4.53 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 6 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, New HIV infections (people). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Long-Acting HIV Treatment market in Germany?
Placeholder estimate: about $107.9 Mn in 2025, rising to about $485.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Germany growing?
Placeholder estimate: about 18.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in Germany?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut. Source: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
How is healthcare paid for in Germany?
Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines. Source: Federal Joint Committee (G-BA). Checked 14 Nov 2026.
How many clinical trials on Long-Acting HIV Treatment are running in Germany?
5 studies are recruiting, active or about to start in Germany, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
What does WHO report for Germany?
New HIV infections: 2,300 people in 2024, the latest WHO figure. Source: WHO Global Health Observatory, New HIV infections (people). Retrieved 15 Nov 2026.
How many people in Germany are 65 or older?
23.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 16 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Germany

See all

Related on hiv and infectious diseases

See the topic